Tariq Rahman, Ph.D., a research scientist at the Alfred I. DuPont Hospital for Children in Wilmington, Delaware, has been awarded a $50,000 Cure SMA clinical care research grant for his project, “Outcome Measures Using WREX – An Upper Extremity Exoskeleton for Children with SMA.” The project will analyze one particular…
News
Global Genes, a leading rare disease patient advocacy organization, recently published a new toolkit titled “From Molecules to Medicines: How Patients Can Share Their Voices Through the Drug Development Process” to address the challenges of patient participation in drug development. According to a press release, the toolkit…
As a part of Cure SMA’s basic research funding, Arthur Burghes, Ph.D., from The Ohio State University, has been awarded $140,000 for his project, “Defining the contribution of RNP assembly pathways to the SMA phenotype.” Burghes’ research will focus on the cellular function of survival motor neuron (SMN) proteins in…
Cure SMA has awarded a $90,000 grant to Antoine Cléry, Ph.D., a researcher at ETH Zurich, for his work on spinal muscular atrophy (SMA), titled “Novel approaches against spinal muscular atrophy by targeting splicing regulators.” The award is part of an $890,000 new basic research fund that…
Cure SMA has just awarded Ohio State University’s Christine Beattie, Ph.D., a $140,000 basic research funding grant for her project on spinal muscular atrophy (SMA): “Identification of SMN:HuD bound RNAs critical for motor neuron development.” Beattie is a professor in OSU’s Department of Neuroscience. She began studying motor…
AveXis recently reported favorable results from an ongoing Phase 1 clinical trial examining its candidate, AVXS-101, for the systematic delivery of gene therapy to young patients with spinal muscular atrophy (SMA). These preliminary results will help inform upcoming trials on gene therapy approaches. The open-label, dose-escalation study evaluating the safety and efficacy of…
RaNA Therapeutics recently released preclinical data on its gene upregulation technology, which selectively triggers gene expression within cells, as a treatment for spinal muscular atrophy (SMA). The data were given in a poster presentation at the recent Keystone Symposium for Chromatin and Epigenetics in British Columbia, Canada. SMA, a major cause of infant mortality, results from mutations or deletions of SMN1 gene…
The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee recently passed an additional seven bills. Cure SMA, a nonprofit organization funding research into new treatments and a possible cure for spinal muscular atrophy (SMA), and providing SMA families with support, observes that along with seven other bills…
FightSMA, an all-volunteer, parent-led nonprofit with a mission to accelerate research for a treatment for spinal muscular atrophy (SMA) by raising awareness and funding for SMA research, is marking its 25th anniversary with an international research conference April 7-9 in Alexandria, Virginia. The meeting will gather leading spinal…
This year’s SMA Researcher Meeting received a record number of abstract submissions, totaling 118 contributions from 14 countries, six different companies, and more than 50 institutions worldwide. The Researcher Meeting is expected to attract more than 300 researchers and clinicians from nearly 100 intuitions, plus other attendants, making this year’s meeting an…
